Efficacy and safety of MYL‐1501D vs insulin glargine in patients with type 1 diabetes after 52?weeks: Results of the INSTRIDE 1 phase III study

摘要

Aim To test the safety and efficacy of MYL‐1501D, a proposed insulin glargine biosimilar, in patients with type 1 diabetes mellitus (T1DM). Methods The safety and efficacy of MYL‐1501D and reference insulin glargine were evaluated in INSTRIDE 1, a 52‐week, open‐label, randomized, phase III study in patients with T1DM. The primary objective was to determine whether once‐daily MYL‐1501D was non‐inferior to once‐daily insulin glargine when administered in combination with mealtime insulin lispro based on change in glycated haemoglobin (HbA1c) from baseline to week 24. Secondary endpoints were changes in fasting plasma glucose, insulin dose, self‐monitored blood glucose and immunogenicity from baseline, and occurrences of hypoglycaemic, nocturnal hypoglycaemic and adverse events up to week 52. Results Overall, 558 patients were randomized 1:1 to MYL‐1501D or reference insulin glargine in combination with thrice‐daily mealtime insulin lispro for 52?weeks. The mean change in HbA1c from baseline to week 24 was 0.14% (standard error [SE] 0.054; 95% confidence interval [CI] 0.033, 0.244) for MYL‐1501D and 0.11% (SE 0.054; 95% CI 0.007, 0.220) for reference insulin glargine. MYL‐1501D had a safety profile similar to that of reference insulin glargine and was well tolerated in patients with T1DM up to week 52. Conclusions The upper 95% CI limit for mean change in HbA1c at week 24 indicated that MYL‐1501D was non‐inferior to reference insulin glargine. There were no clinically meaningful differences between groups in incidence of overall and nocturnal hypoglycaemia, local or systemic reactions, safety or immunogenicity.